Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of vorinostat when given
together with doxorubicin in treating patients with metastatic or locally advanced solid
tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as doxorubicin, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Vorinostat may help doxorubicin work better by making tumor cells more sensitive to
the drug.